Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin plus metformin versus empagliflozin or metformin alone in drug-naive type 2 diabetes
2010-021375-92Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin and metformin in type 2 diabetes mellitus (T2DM) (8 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in HbA1c after 24 weeks of treatment. Started Jun 2012; status: completed.
02
Drugs
empagliflozinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-021375-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021375-92.